Who owns Viking Therapeutics, Inc. (VKTX)? Elite investor 13F holders
4 tracked elite investors reported holding Viking Therapeutics, Inc as of 2026-06-30, including D.E. Shaw, Gotham Asset Management, Bridgewater Associates, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | VIKING THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 62649826.00 USD | 1605994.000000 | Shares | reduce | Original filing |
| Gotham Asset Management | VIKING THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 9001050.00 USD | 230737.000000 | Shares | reduce | Original filing |
| Bridgewater Associates | VIKING THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3427380.00 USD | 87859.000000 | Shares | add | Original filing |
| Tudor Investment | VIKING THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Ancora Advisors / Ancora Holdings | VIKING THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 22236.00 USD | 570.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.